Literature DB >> 31773242

Robotic versus other nephroureterectomy techniques: a systematic review and meta-analysis of over 87,000 cases.

Alessandro Veccia1,2, Alessandro Antonelli2, Simone Francavilla2, Claudio Simeone2, Georgi Guruli1, Homayoun Zargar3, Sisto Perdoná4, Matteo Ferro5, Giuseppe Carrieri6, Lance J Hampton1, Francesco Porpiglia7, Riccardo Autorino8.   

Abstract

PURPOSE: To perform a systematic review and meta-analysis of the literature inherent robotic nephroureterectomy (RNU) and to compare its outcomes with those of other nephroureterectomy (NU) techniques.
METHODS: A systematic literature search was performed up to April 2019 using PubMed, Embase®, and Web of Science. The Preferred Reporting Items for Systematic Review and Meta-analysis Statement was followed for study selection. The following data were extracted for each study: baseline features, surgical outcomes, oncological outcomes, and survival outcomes. Stata® 15.0 was used for statistical analysis.
RESULTS: Literature search identified 80 studies eligible for the meta-analysis and overall 87,291 patients were included in the analysis: open NU (ONU; n = 45,601), hand-assisted laparoscopic NU (HALNU; n = 442), laparoscopic NU (LNU n = 31,093), and RNU (n = 10,155). RNU was more likely to be performed in those patients with multifocal tumor location (proportion: 0.19; 95% CI 0.14, 0.24) and high-grade disease (proportion: 0.70; 95% CI 0.53, 0.68). The lowest EBL was recorded in the RNU group (weighted mean (WM) 163.31 mL; 95% CI 88.94, 237.68), whereas the highest was in the ONU group (414.99 mL; 95% CI 378.52, 451.46). Operative time was shorter for ONU (224.98 mL; 95% CI 212.26, 237.69). RNU had lower rate of intraoperative complications (0.02; 95% CI 0.01, 0.05). ONU showed higher odds of transfusions (0.20; 95% CI 0.15, 0.25). LOS was statistically significantly shorter for the RNU group (5.35 days; 95% CI 4.97, 5.82). HALNU seemed to present lower risk of PSM (0.02; 95% CI - 0.01, 0.05), and lower risk of recurrence (0.22; 95% CI 0.15, 0.30), metastasis (0.07; 95% CI 0.05, 0.10), and cancer-related death (0.03; 95% CI 0.01, 0.06). ONU showed the lowest 5 years cancer specific survival (proportion: 0.77; 95% CI 0.74, 0.80). No correlation was found between the surgical technique and recurrence-free and cancer-specific survival.
CONCLUSIONS: Evidence regarding RNU for the treatment of UTUC is increasing but it remains quite sparse and of low quality. Despite this, RNU seems to be safe, and to offer the advantages of a minimally invasive approach without impairing the oncological outcomes. Nevertheless, ONU, HALNU, and LNU still represent a valid, and commonly used surgical treatment option. As RNU becomes more popular, and concerns related to its use remain, the best surgical technique for NU remains to be determined.

Entities:  

Keywords:  Hand-assisted radical nephroureterectomy; Laparoscopic radical nephroureterectomy; Open radical nephroureterectomy; Robotic radical nephroureterectomy; Upper tract urothelial carcinoma

Year:  2019        PMID: 31773242     DOI: 10.1007/s00345-019-03020-1

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  8 in total

Review 1.  Robotic surgery in comparison to the open and laparoscopic approaches in the field of urology: a systematic review.

Authors:  Afra Zahid; Muhammad Ayyan; Minaam Farooq; Huzaifa Ahmad Cheema; Abia Shahid; Faiza Naeem; Muhammad Abdullah Ilyas; Shehreen Sohail
Journal:  J Robot Surg       Date:  2022-05-08

Review 2.  Robotic nephroureterectomy in the management of upper tract urothelial cancer: inching toward standard of care?

Authors:  Sumit Saini; Ram Anil Pathak; Ashok Kumar Hemal
Journal:  Int Urol Nephrol       Date:  2022-05-24       Impact factor: 2.266

3.  Laparoscopic radical cystectomy and nephroureterectomy en bloc resection with lomboaortic and pelvic lymph node dissection.

Authors:  Bogdan Petruţ; Roxana-Andra Coman; Vlad Hârdo; Bogdan Coste; Teodor Maghiar
Journal:  Med Pharm Rep       Date:  2020-10-25

4.  Role of the Laparoscopic Approach for Complex Urologic Surgery in the Era of Robotics.

Authors:  Iulia Andras; Angelo Territo; Teodora Telecan; Paul Medan; Ion Perciuleac; Alexandru Berindean; Dan V Stanca; Maximilian Buzoianu; Ioan Coman; Nicolae Crisan
Journal:  J Clin Med       Date:  2021-04-21       Impact factor: 4.241

5.  Effects of robot-assisted versus hand-assisted nephroureterectomy on circulating tumor cells for upper urinary tract urothelial carcinoma.

Authors:  Hui-Kung Ting; Tai-Lung Cha; Yi-Ta Tsai; Shu-Yu Liu; Sheng-Tang Wu; En Meng; Chih-Wei Tsao; Chien-Chang Kao; Chin-Li Chen; Guang-Huan Sun; Dah-Shyong Yu; Ming-Hsin Yang
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

6.  Comparing Oncological Outcomes and Surgical Complications of Hand-Assisted, Laparoscopic and Robotic Nephroureterectomy for Upper Tract Urothelial Carcinoma.

Authors:  Ching-Chia Li; Chao-Hsiang Chang; Chi-Ping Huang; Jian-Hua Hong; Chao-Yuan Huang; I-Hsuan Alan Chen; Jen-Tai Lin; Chi-Wen Lo; Chih-Chin Yu; Jen-Shu Tseng; Wun-Rong Lin; Wei-Che Wu; Shiu-Dong Chung; Thomas Y Hsueh; Allen W Chiu; Yung-Tai Chen; Shin-Hong Chen; Yuan-Hong Jiang; Yao-Chou Tsai; Bing-Juin Chiang; Wei Yu Lin; Yeong-Chin Jou; Chia-Chang Wu; Hsiang-Ying Lee; Hsin-Chih Yeh
Journal:  Front Oncol       Date:  2021-10-04       Impact factor: 6.244

7.  First completely robot-assisted retroperitoneal nephroureterectomy with bladder cuff: a step-by-step technique.

Authors:  P Sparwasser; S Epple; A Thomas; R Dotzauer; K Boehm; M P Brandt; R Mager; H Borgmann; M M Kamal; M Kurosch; T Höfner; A Haferkamp; I Tsaur
Journal:  World J Urol       Date:  2022-01-17       Impact factor: 3.661

8.  Robot-assisted vs. laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and meta-analysis based on comparative studies.

Authors:  Ruoyu Ji; Zhangyuting He; Shiyuan Fang; Wenjie Yang; Mengchao Wei; Jie Dong; Weifeng Xu; Zhigang Ji
Journal:  Front Oncol       Date:  2022-08-03       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.